Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?

Non-viral methods for ex vivo cell & gene therapy: is the future non-viral? In this episode, Valeria Annibaldi and Andrea Toell discuss the types and benefits of non-viral methods for ex vivo cell and gene therapy in addition to the readiness of electroporation-based technologies for use in GMP manufacturing.

To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website

Chapters

• 1:51 What non-viral methods are used in the space, and do you see their use evolving?
• 4:20 What are the advantages and disadvantages of utilizing non-viral technology for ex vivo cell therapy?
• 8:07 How can the challenge of transfecting cell types using non-viral means be overcome?
• 9:50 What non-viral gene transfer technology does Lonza offer?
• 12:11 What advantages does an electroporation-based method offer?
• 15:57 Is electroporation-based technology scalable to meet the needs of the industry?
• 17:54 What non-viral technologies are being used in clinical or commercial applications based on ex vivo modifications?
• 19:01 What are your predictions for the future of this space?